Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 The development of dendritic cell vaccine-based immunotherapies for glioblastoma.

Literature DB >> 28138787

The development of dendritic cell vaccine-based immunotherapies for glioblastoma.

Abstract

In this review, we focus on the biologic advantages of dendritic cell-based vaccinations as a therapeutic strategy for cancer as well as preclinical and emerging clinical data associated with such approaches for glioblastoma patients.

Entities: Disease Species

Mesh：

Substances：

Year: 2017 PMID： 28138787 DOI： 10.1007/s00281-016-0616-7

Source DB: PubMed Journal: Semin Immunopathol ISSN： 1863-2297 Impact factor: 9.623

141 in total

1. An in vivo model of priming of antigen-specific human CTL by Mo-DC in NOD/Shi-scid IL2rgamma(null) (NOG) mice.

Authors: Mitsuhiro Inoue; Satoru Senju; Shinya Hirata; Atsushi Irie; Hideo Baba; Yasuharu Nishimura
Journal: Immunol Lett Date: 2009-08-12 Impact factor: 3.685

2. Treatment of a patient by vaccination with autologous dendritic cells pulsed with allogeneic major histocompatibility complex class I-matched tumor peptides. Case Report.

Authors: L M Liau; K L Black; N A Martin; S N Sykes; J M Bronstein; L Jouben-Steele; P S Mischel; A Belldegrun; T F Cloughesy
Journal: Neurosurg Focus Date: 2000-12-15 Impact factor: 4.047

Review 3. Dendritic cell-targeted vaccines--hope or hype?

Authors: Wolfgang Kastenmüller; Kathrin Kastenmüller; Christian Kurts; Robert A Seder
Journal: Nat Rev Immunol Date: 2014-09-05 Impact factor: 53.106

4. Endogenous Neoantigen-Specific CD8 T Cells Identified in Two Glioblastoma Models Using a Cancer Immunogenomics Approach.

Authors: Tanner M Johanns; Jeffrey P Ward; Christopher A Miller; Courtney Wilson; Dale K Kobayashi; Diane Bender; Yujie Fu; Anton Alexandrov; Elaine R Mardis; Maxim N Artyomov; Robert D Schreiber; Gavin P Dunn
Journal: Cancer Immunol Res Date: 2016-10-31 Impact factor: 11.151

Review 5. Treating recurrent glioblastoma: an update.

Authors: Carlos Kamiya-Matsuoka; Mark R Gilbert
Journal: CNS Oncol Date: 2015

6. A randomized trial of bevacizumab for newly diagnosed glioblastoma.

Authors: Mark R Gilbert; James J Dignam; Terri S Armstrong; Jeffrey S Wefel; Deborah T Blumenthal; Michael A Vogelbaum; Howard Colman; Arnab Chakravarti; Stephanie Pugh; Minhee Won; Robert Jeraj; Paul D Brown; Kurt A Jaeckle; David Schiff; Volker W Stieber; David G Brachman; Maria Werner-Wasik; Ivo W Tremont-Lukats; Erik P Sulman; Kenneth D Aldape; Walter J Curran; Minesh P Mehta
Journal: N Engl J Med Date: 2014-02-20 Impact factor: 91.245

7. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.

Authors: Roger Stupp; Monika E Hegi; Warren P Mason; Martin J van den Bent; Martin J B Taphoorn; Robert C Janzer; Samuel K Ludwin; Anouk Allgeier; Barbara Fisher; Karl Belanger; Peter Hau; Alba A Brandes; Johanna Gijtenbeek; Christine Marosi; Charles J Vecht; Karima Mokhtari; Pieter Wesseling; Salvador Villa; Elizabeth Eisenhauer; Thierry Gorlia; Michael Weller; Denis Lacombe; J Gregory Cairncross; René-Olivier Mirimanoff
Journal: Lancet Oncol Date: 2009-03-09 Impact factor: 41.316

8. Murine epidermal Langerhans cells and splenic dendritic cells present tumor-associated antigens to primed T cells.

Authors: P J Cohen; P A Cohen; S A Rosenberg; S I Katz; J J Mulé
Journal: Eur J Immunol Date: 1994-02 Impact factor: 5.532

9. Novel role of hematopoietic stem cells in immunologic rejection of malignant gliomas.

Authors: Catherine Flores; Christina Pham; David Snyder; Shicheng Yang; Luis Sanchez-Perez; Elias Sayour; Xiuyu Cui; Hanna Kemeny; Henry Friedman; Darell D Bigner; John Sampson; Duane A Mitchell
Journal: Oncoimmunology Date: 2015-01-22 Impact factor: 8.110

Review 10. Immunocompetent murine models for the study of glioblastoma immunotherapy.

Authors: Taemin Oh; Shayan Fakurnejad; Eli T Sayegh; Aaron J Clark; Michael E Ivan; Matthew Z Sun; Michael Safaee; Orin Bloch; Charles D James; Andrew T Parsa
Journal: J Transl Med Date: 2014-04-29 Impact factor: 5.531

8 in total

1. Dendritic cells in autoimmunity, infections, and cancer.

Authors: Francisco J Quintana
Journal: Semin Immunopathol Date: 2017-01-16 Impact factor: 9.623

2. LncRNA SAMMSON Knockdown Inhibits the Malignancy of Glioblastoma Cells by Inactivation of the PI3K/Akt Pathway.

Authors: Hongzao Ni; Kai Wang; Peng Xie; Jiandong Zuo; Wenguang Liu; Chun Liu
Journal: Cell Mol Neurobiol Date: 2020-03-31 Impact factor: 5.046

3. Ubiquitin-specific protease 4 promotes glioblastoma multiforme via activating ERK pathway.

Authors: Yudong Zhou; Ping Liang; Wenyuan Ji; Zengpeng Yu; Hui Chen; Li Jiang
Journal: Onco Targets Ther Date: 2019-03-05 Impact factor: 4.147

4. Expansion of effector and memory T cells is associated with increased survival in recurrent glioblastomas treated with dendritic cell immunotherapy.

Authors: Marica Eoli; Cristina Corbetta; Elena Anghileri; Natalia Di Ianni; Micaela Milani; Valeria Cuccarini; Silvia Musio; Rosina Paterra; Simona Frigerio; Sara Nava; Daniela Lisini; Sara Pessina; Luisa Maddaloni; Raffaella Lombardi; Maria Tardini; Paolo Ferroli; Francesco DiMeco; Maria Grazia Bruzzone; Carlo Antozzi; Bianca Pollo; Gaetano Finocchiaro; Serena Pellegatta
Journal: Neurooncol Adv Date: 2019-08-20